Friday, Nov 20, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Hyderabad | Eisai Launches Leqembi For Early Alzheimers Disease Treatment In India

Eisai launches LEQEMBI for early Alzheimer’s disease treatment in India

Eisai has launched LEQEMBI (lecanemab) in India after receiving CDSCO approval, introducing the country's first disease-modifying therapy for early Alzheimer's disease. The treatment is indicated for patients with mild cognitive impairment and mild dementia and aims to slow disease progression.

By Telangana Today
Published Date - 3 August 2026, 06:00 PM
Eisai launches LEQEMBI for early Alzheimer’s disease treatment in India
whatsapp facebook twitter telegram

Hyderabad: Eisai, the noted Japanese pharmaceutical company headquartered, announced the launch of Leqembi (lecanemab) for treatment of early Alzheimer’s disease, following marketing authorisation from Central Drugs Standard Control Organization (CDSCO).

In India, LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer’s disease, marking the introduction of this first-of-its-kind Disease-Modifying Therapy (DMT) in the country’s Alzheimer’s disease treatment landscape, the pharma company said in a statement on Monday.


LEQEMBI has received approvals in several developed markets including the United States, Japan and across Europe, as well as select developing countries. Further, there is emerging real-world experience indicating the potential value of LEQEMBI in slowing disease progression and improving patient outcomes, Eisai said.

LEQEMBI (lecanemab) is a humanised monoclonal antibody that selectively targets aggregated amyloid-beta, enabling its clearance while reducing further deposition. It is approved for use in early-stage Alzheimer’s disease, including MCI and mild dementia.

“What is promising about LEQEMBI (lecanemab) is its ability to intervene early in the disease process,” said Ritesh Jain, Head of Commercial Operations, Eisai India.

Access and awareness remain critical barriers in Alzheimer’s disease care in India. Our support programmes are aimed at helping eligible patients initiate and continue therapy, in line with our human health care philosophy,” Takuya Kijima, Managing Director, Eisai India, said.

Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • Alzheimer's disease
  • Central Drugs Standard Control Organization (CDSCO)
  • Hyderabad News
  • Telangana News

Related News

  • Hyderabad: TGSRTC removes driver over rude behaviour

    Hyderabad: TGSRTC removes driver over rude behaviour

  • Three couples realise parenthood dream through IVF at Gandhi Hospital

    Three couples realise parenthood dream through IVF at Gandhi Hospital

  • Governor inaugurates IIMUN Hyderabad Conference 2026

    Governor inaugurates IIMUN Hyderabad Conference 2026

  • Telangana opens Mee Seva route for borewell permissions

    Telangana opens Mee Seva route for borewell permissions

Latest News

  • Anirudh Ravichander and Kavya Maran thank fans after Greece wedding

    42 seconds ago
  • Anthropic IPO creates 600 employees with stakes worth over $100 million

    5 minutes ago
  • Anish Giri beats Firouzja, takes 11–9 lead in chess final

    13 minutes ago
  • Sensex plunges 615 points, Nifty slips as global sell-off rattles markets

    49 minutes ago
  • Woman dies in accident after CM Revanth’s meeting in Siddipet

    50 minutes ago
  • Fire engulfs electric car after truck collision on Hyderabad ORR

    1 hour ago
  • Apple-laden truck overturns on Hyderabad-Vijayawada highway, driver injured

    1 hour ago
  • Hey Kannamma gets U/A certificate ahead of November 27 release

    2 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App